World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 


A miracle treatment for TB is a near possibility

New Drug Regimen: A miracle treatment for TB is a near possibility

Shobha Shukla, Citizen News Service (CNS)

Two years after launching a first of its kind Combination Drug Study for TB treatment in 2010, the Global Alliance for TB Drug Development (TB Alliance) raised hopes of a novel drug regimen to treat both forms of TB—drug sensitive (DS) and multi drug resistant (MDR) TB, at the XX International AIDS Conference (AIDS 2014) in Melbourne, offering a new paradigm in TB treatment to treat patients with drugs to which they are sensitive, rather than based on what they are resistant to.

Announcing the results of the PaMZ Phase 2b trial results, Dr Dan Everitt, Senior Medical Officer of TB Alliance, informed that the new combination drug regimen PaMZ is designed to treat both DS-TB and some forms of MDR-TB (which are not resistant to Moxifloxacin and Pyrazinamide) in a much shorter time.

PaMZ consists of two new drug candidates, PA-824 (Pa) and moxifloxacin (M) and pyrazinamide (Z) which is part of the current first-line treatment.

In an interview given to Citizen News Service (CNS), Dr Everitt said that, “We are extremely encouraged by the results of this trial. They were consistent with our predictions from earlier research and add strong evidence to support our belief that we are well on the way to substantially improved treatment for TB and many MDR-TB patients.”

The new regimen raises new hopes of having a much shorter, simpler, cheaper and effective treatment for DS-TB and MDR-TB. In case of MDR-TB, it not only promises to reduce treatment time to 6 months from the current 24 months, but also reduces 97% of the pill burden (from the existing over 14000 pills to 360 pills) and eliminates totally the need of injections. At the same time it also avoids interactions with antiretroviral drugs, improving treatment for the millions of HIV-TB co-infected patients.

Dr Everitt elaborated that this open-label randomized clinical trial to study the bactericidal activity of 8-weeks treatment with PaMZ in DS-TB and MDR-TB, was performed at 7 sites (5 in South Africa and 2 in Tanzania) on 181 DS-TB and 26 MDR-TB subjects, of whom 35% were female, and 20% were HIV-infected. However only 9 MDR-TB subjects could be included in the statistical analysis of the 8 weeks data, as others were late exclusions, as they were found resistant to pyrazinamide, and therefore ineligible for the trial.

The PaMZ regimen showed active bactericidal activity against both DS-TB and MDR-TB that extended from 2 weeks through 2 months and which was significantly greater than that of the existing standard HRZE (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) therapy in patients with DS-TB. All 3 experimental treatment arms had greater average reductions in CFU (colony forming units) counts than HRZE over 8 weeks.

When evaluated with the most sensitive diagnostic methods available (liquid culture), nearly twice as many TB patients treated with PaMZ (71%) produced TB-negative sputum cultures at the end of 2 month course of the trial, compared to patients treated with standard HRZE therapy (38%).

Thus PaMZ killed more bacteria than standard therapy and did so at a faster rate for both DS-TB and MDR-TB. It also showed compatibility with commons anti retro viral drugs (ARVs) as there appeared to be no interference or side effects between the PaMZ regimen and the common ARVs being taken by the TB-HIV co-infected patients. A formal statistical evaluation found no effect of HIV status on the outcome of the study. Also side effect profiles were encouraging and appeared consistent between both TB and MDR-TB patients.

TB Alliance, with the help of its global partners, now plans to advance PaMZ to a first ever global phase 3 clinical study named STAND (Shortening Treatments by Advancing Novel Drugs) by the end of 2014, testing a drug regimen for use against both DS-TB and MDR-TB, provided adequate funding is secured. STAND aims to enroll more than 1500 patients in more than 50 sites in 15 countries (spanning South Africa, Kenya, Tanzania, Uganda, Zambia, Malaysia, Thailand, China, Philippines, Peru, Brazil, Georgia, Ukraine, Russia, and Haiti), which will include a significantly larger number of MDR-TB patients.

If PaMZ performs successfully in the STAND trial, it will proceed to global registration and be made available to the people who need it.

STAND not only represents the hope of new TB cures, but also the promise of an innovative scientific approach to developing new products. If the STAND trial is successful, it will mark the first time a new TB drug regimen is developed and registered using a new model pioneered by TB Alliance that allows multiple new drugs to be developed at once –making a combination of drugs, and not a single drug, the basis for innovation.

Globally, every year 1.3 million people die from TB, while nearly 9 million more contract it. Also the disease is becoming increasingly resistant to the available drugs. Today, 650,000 patients around the world suffer from MDR-TB, and this number is expected to continue to rise. Most MDR-TB patients are unable to access adequate treatment due to the complexity and high cost of treatment. New regimens that are shorter, less costly, better tolerated, oral and compatible with anti-retroviral therapy are urgently needed to treat TB, especially MDR-TB.

Dr Mel Spigelman, President and CEO, TB Alliance told CNS that, “PaMZ continues to show game-changing potential for TB, and especially MDR-TB patients, as well as those co-infected with TB and HIV. We are working as quickly and diligently as possible to begin the next and final stage of PaMZ’s development, and continuing to seek financial support for STAND”.

ENDS

© Scoop Media

 
 
 
 
 
World Headlines

 

Ban Condemns Killing Of Former Lesotho Military Commander

United Nations Secretary-General today condemned the killing of Lt. Gen. Maaparankoe Mahao, former Commander of the Lesotho Defence Force, on 25 June, near Maseru. More>>

Ban Welcomes US Supreme Court Ruling On Same-Sex Marriage

Ban welcomes US Supreme Court ruling guaranteeing right to same-sex marriage Lesbian, Gay, Bisexual, Transgender and Intersex (LGBTI) pride march. Photo: OHCHR/Joseph Smida More>>

UN Agency Welcomes EU Measures On Refugee Arrivals

Afghan refugees in front of the abandoned hotel Captain Elias on Kos Island, Greece, where hundreds of refugees and migrants are waiting for their registration. Photo: UNHCR/J. Akkash More>>

Increase In Voluntary Blood Donors Can Save Millions Of Lives

Increase in voluntary blood donors can save millions of lives, UN health agency says on World Day More>>

Kenya: Funding Shortage Means Food Cut To 500,000 Refugees

Funding shortage forces UN agency to temporarily cut food aid to 500,000 refugees in Kenya More>>

UN Launches Education Appeal In Fight Against Child Labour

12 June 2015 – The United Nations has announced it is marking the 2015 edition of the World Day Against Child Labour with a call for the international community to invest in quality education as a key step in the fight against child employment ... More>>

Pope Francis & UN Agency On Sustainability Of Agriculture

Pope Francis (centre) with delegates to the 39th FAO Conference during a special audience at the Vatican. Photo: FAO More>>

South Sudan: Call For De-Escalation Of In-Country Conflict

Women and children have suffered devastating attacks in South Sudan’s Unity State. Photo: UNICEF/South Sudan/Sebastian Rich More>>

Burundi: Emergency Support To Refugees Fleeing Burundi Crisis

Burundians fleeing pre-election violence rest on the shores of Lake Tanganyika in the Democratic Republic of Congo after a gruelling 22-hour boat journey. More than 100,000 Burundians have fled over the past month, arriving in Tanzania, Rwanda and ... More>>

Afghanistan: Commitment To Advancing Women's Rights

While the outgoing senior United Nations rights official in Afghanistan said she expected the human rights advances made “will be sustained, will not be rolled back, and will not be sacrificed,” she lamented the high level of violence against ... More>>

Get More From Scoop

 
 
 
 
 
World
Search Scoop  
 
 
Powered by Vodafone
NZ independent news